Bristol Myers Squibb is committed to helping appropriate patients get access to our medications by providing access and reimbursement support services.

This information is intended for U.S. healthcare professionals and/or healthcare professionals involved in healthcare reimbursement.

Billing and
Diagnosis Codes

Reimbursement and Coding Guide for REVLIMID

The information below is designed to help appropriate patients get access to REVLIMID by providing helpful reimbursement information for healthcare offices. It is important that offices verify each patient’s insurance coverage prior to initiating therapy. BMS Access Support may be able to help.

Multiple Myeloma

View Codes >

Myelodysplastic Syndromes

View Codes >

Relapsed Mantle Cell Lymphoma

View Codes >

Previously Treated Follicular Lymphoma

View Codes >

Previously Treated Marginal Zone Lymphoma

View Codes >

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

BMS Logo

2003-US-2100246 06/21

©2021 Bristol-Myers Squibb Company. All rights reserved. Access Support is a registered trademark of Bristol-Myers Squibb Company. REVLIMID® is a registered trademark of Celgene Corporation, a Bristol Myers Squibb company.

Use of the information on this site is subject to the terms of our Legal Notice and Privacy Statement. The coding, coverage, and payment information contained within this website is current as of 05/21.

2003-US-2100005 05/21